Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report

INTRODUCTION: Ulcerative colitis is an immune-mediated disease that carries challenges in pediatrics since it's frequently severe and extensive. Current pediatric ulcerative colitis guidelines offer a weak recommendation regarding the usage and the dosage of golimumab in low-weight children. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhalabi, Marouf M., Abbas, Ahmad J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977938/
https://www.ncbi.nlm.nih.gov/pubmed/35386809
http://dx.doi.org/10.1016/j.amsu.2022.103456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977938/
https://www.ncbi.nlm.nih.gov/pubmed/35386809
http://dx.doi.org/10.1016/j.amsu.2022.103456

Ejemplares similares